The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial

Journal of Infection and Chemotherapy - 1w ago Preview

 
 
• AUTO POST
 
• SAVE TO EVERNOTE

Publication date: Available online 18 May 2019

Source: Journal of Infection and Chemotherapy

Author(s): Taiga Miyazaki, Shigeki Nakamura, Kohji Hashiguchi, Tsutomu Kobayashi, Kiyoyasu Fukushima, Yuichi Fukuda, Akira Kondo, Yuichi Inoue, Hironobu Koga, Eisuke Sasaki, Yosuke Nagayoshi, Yasuhito Higashiyama, Masataka Yoshida, Takahiro Takazono, Tomomi Saijo, Yoshitomo Morinaga, Kazuko Yamamoto, Yoshifumi Imamura, Shinya Mikushi, Koichi Izumikawa

Abstract

Oral treatment for elderly outpatients with pneumonia is becoming increasingly important in this super-aged society from the perspective of cost-effectiveness and limited hospital capacities. We evaluated the efficacy and safety of two oral respiratory quinolones, sitafloxacin and garenoxacin, in elderly patients with pneumonia. This randomized, multicenter, open-label trial was conducted among patients aged ≥65 years with clinically and radiographically confirmed pneumonia in Japan. Patients were randomly assigned (1:1) to receive either sitafloxacin (100 mg/day) or garenoxacin (400 mg/day) for 3–10 days. The primary efficacy endpoint was the clinical cure rate at 5–10 days after the end of treatment. From December 2013 to November 2017, we enrolled 120 patients at 11 hospitals and randomly assigned 59 patients to the sitafloxacin group (1 patient withdrew) and 61 patients to the garenoxacin group. These included 30 patients with nursing and healthcare-associated pneumonia (NHCAP) (18 receiving sitafloxacin, 12 receiving garenoxacin) and 37 patients with aspiration pneumonia (16 receiving sitafloxacin, 21 receiving garenoxacin). The clinical cure rates in the sitafloxacin and garenoxacin groups were 88.5% (95% confidence interval: 76.6–95.6) and 88.9% (95% confidence interval: 77.4–95.8), respectively. No significant differences were observed in the incidence rates of drug-related adverse events between the sitafloxacin (20.7%; 12/58 patients) and garenoxacin (27.9%; 17/61 patients) groups. The most common adverse event was hepatic dysfunction, which occurred in seven patients in each group. We conclude that sitafloxacin and garenoxacin are comparably effective and safe for the treatment of pneumonia, including NHCAP and aspiration pneumonia, in elderly patients.